<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="16522" whole_study_id="5932" phs="000260" v="4" p="2" createDate="2015-08-31T15:18:43-05:00" completedByGPADate="2016-03-08T14:26:03-05:00" modDate="2020-01-23T01:36:48-05:00" maxParentChildStudyModDate="2020-01-23T01:36:48-05:00" handle="HMP_ForegutEsophagealAdenocarcinoma" num_participants=""><StudyInfo accession="phs000260.v4.p2" parentAccession="phs000260.v4.p2"><BioProject id="PRJNA46307" entrez_id="46307" type="bp_data_submission"/><BioProject id="PRJNA74953" entrez_id="74953" type="bp_admin_access"/><StudyNameEntrez>Foregut microbiome in development of esophageal adenocarcinoma</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>sra</StudyType><StudyType>metagenomics</StudyType></StudyTypes><SraStorages/><Funding>UH2 CA140233-01</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="PEIZ01" aid="2" auth="eRA" login="PEIZ01" fname="ZHIHENG" lname="PEI" email="zhiheng.pei@med.nyu.edu"><Role>PI</Role><Organization>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</Organization></Person><Person nedid="0010142285" aid="1" auth="cit" login="howcrofk" fname="Thomas" mname="K" lname="Howcroft" email="howcrofk@exchange.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person aid="8" auth="virtual" fname="Stuart" lname="Brown" email="stuart.brown@nyumc.org"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2001203526" aid="1" auth="cit" login="cagaananef" fname="Emilie" mname="Charlisse F" lname="Caga-Anan" email="charlisse.caga-anan@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>Funding support for the Study of Foregut Microbiome in Development of Esophageal Adenocarcinoma was provided by the National Cancer Institute (UH2CA140233) through the Human Microbiome Project of the NIH Roadmap Initiative. Data for the Foregut Microbiome study were provided by Zhiheng Pei MD, PhD on behalf of his collaborators at New York University School of Medicine, the J. Craig Venter Institute, and Lawrence Berkeley National Laboratory.</acknowledgement_statement><ic_specific_access_term/><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="unrest_access_by_timeout" gsr_mode_label="Unrestricted access (institution did not respond within six months)"/><ConsentGroup uid="559" CGType="" title="Human Microbiome Research" name="HMP" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No"><Use-Restriction>These data may be used only for studies related to the human microbiome. Research aimed at understanding the relationships between humans and microbes or identifying the organisms living in or on humans.  This includes studies to enumerate the population of the human microbiome, metagenomic studies, functional studies related to the human microbiome, studies that evaluate the impact of the human microbiome on human phenotypes or disease states, studies to develop technologies and analytic tools that can be used in human microbiome research, and studies that will use the data in a way that will contribute to the further understanding of the human microbiome through comparison with non-human data sets.  
Sequence data generated from microbiome samples will be used only for the purpose of studying the microbial components of the microbiome and will not be used to make inferences about the human host DNA itself.
</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="7275" whole_study_id="5932" phs="000260" v="3" p="2" createDate="2011-08-17T16:31:49-05:00" modDate="2020-09-01T10:28:45-05:00" maxParentChildStudyModDate="2020-09-01T10:28:45-05:00" handle="HMP_ForegutEsophagealAdenocarcinoma" num_participants=""><StudyInfo accession="phs000260.v3.p2" parentAccession="phs000260.v3.p2"><BioProject id="PRJNA46307" entrez_id="46307" type="bp_data_submission"/><BioProject id="PRJNA74953" entrez_id="74953" type="bp_admin_access"/><StudyNameEntrez>Foregut microbiome in development of esophageal adenocarcinoma</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>sra</StudyType><StudyType>metagenomics</StudyType></StudyTypes><SraStorages/><Funding>UH2 CA140233-01</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="PEIZ01" aid="2" auth="eRA" login="PEIZ01" fname="ZHIHENG" lname="PEI" email="zhiheng.pei@med.nyu.edu"><Role>PI</Role><Organization>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</Organization></Person><Person nedid="0010142285" aid="1" auth="cit" login="howcrofk" fname="Thomas" mname="K" lname="Howcroft" email="howcrofk@exchange.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2001203526" aid="1" auth="cit" login="cagaananef" fname="Emilie" mname="Charlisse F" lname="Caga-Anan" email="charlisse.caga-anan@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="12 months"><DUC><File uri="dbgapssws.cgi?blob_id=6617&amp;file=get&amp;page=file" filename="Data Use Certification - Foregut Microbiome in Development of Esophageal Adenocarcinoma - Revised 1.26.11.doc" md5="4ac3aae1806f7d1af3a67ab1f14b3ac0" size="75776" modDate="2011-01-26T13:48:14-05:00" content-type="application/msword"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=14949&amp;file=get&amp;page=file" filename="Data Use Certification - Foregut Microbiome in Development of Esophageal Adenocarcinoma - Revised 1.26.11.doc.pdf" md5="df09d0b2d65062234eaed1696f823d13" size="92286" modDate="2015-06-18T17:51:55-05:00" content-type="application/pdf"/></DUC_PDF><ConsentGroup uid="559" CGType="cg_class_other" title="Human Microbiome Research" name="HMP" dac_uid="62" dac_name="eNCI DAC" irb-approval-required="No"><Use-Restriction>These data may be used only for studies related to the human microbiome. Research aimed at understanding the relationships between humans and microbes or identifying the organisms living in or on humans.  This includes studies to enumerate the population of the human microbiome, metagenomic studies, functional studies related to the human microbiome, studies that evaluate the impact of the human microbiome on human phenotypes or disease states, studies to develop technologies and analytic tools that can be used in human microbiome research, and studies that will use the data in a way that will contribute to the further understanding of the human microbiome through comparison with non-human data sets.  
Sequence data generated from microbiome samples will be used only for the purpose of studying the microbial components of the microbiome and will not be used to make inferences about the human host DNA itself.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="6595" whole_study_id="5932" phs="000260" v="2" p="1" createDate="2011-01-14T15:32:08-05:00" modDate="2020-09-01T10:26:26-05:00" maxParentChildStudyModDate="2020-09-01T10:26:26-05:00" handle="HMP_ForegutEsophagealAdenocarcinoma" num_participants=""><StudyInfo accession="phs000260.v2.p1" parentAccession="phs000260.v2.p1"><StudyNameEntrez>Foregut microbiome in development of esophageal adenocarcinoma</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="No"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>sra</StudyType><StudyType>metagenomics</StudyType></StudyTypes><SraStorages/><Funding>UH2 CA140233-01</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="PEIZ01" aid="2" auth="eRA" login="PEIZ01" fname="ZHIHENG" lname="PEI" email="zhiheng.pei@med.nyu.edu"><Role>PI</Role><Organization>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</Organization></Person><Person nedid="0010142285" aid="1" auth="cit" login="howcrofk" fname="Thomas" mname="K" lname="Howcroft" email="howcrofk@exchange.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2000633685" aid="1" auth="cit" login="buccinild" fname="Laura" mname="Danielle" lname="Buccini" email="none"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="12 months"><DUC><File uri="dbgapssws.cgi?blob_id=6617&amp;file=get&amp;page=file" filename="Data Use Certification - Foregut Microbiome in Development of Esophageal Adenocarcinoma - Revised 1.26.11.doc" md5="4ac3aae1806f7d1af3a67ab1f14b3ac0" size="75776" modDate="2011-01-26T13:48:14-05:00" content-type="application/msword"/></DUC><ConsentGroup uid="363" CGType="cg_class_other" title="Human Microbiome Research" name="HMP" dac_uid="62" dac_name="eNCI DAC" irb-approval-required="No"><Use-Restriction>These data may be used only for studies related to the human microbiome. Research aimed at understanding the relationships between humans and microbes or identifying the organisms living in or on humans.  This includes studies to enumerate the population of the human microbiome, metagenomic studies, functional studies related to the human microbiome, studies that evaluate the impact of the human microbiome on human phenotypes or disease states, studies to develop technologies and analytic tools that can be used in human microbiome research, and studies that will use the data in a way that will contribute to the further understanding of the human microbiome through comparison with non-human data sets.  
Sequence data generated from microbiome samples will be used only for the purpose of studying the microbial components of the microbiome and will not be used to make inferences about the human host DNA itself.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study><Study uid="5932" whole_study_id="5932" phs="000260" v="1" p="1" createDate="2010-02-18T09:06:48-05:00" modDate="2020-09-01T10:56:53-05:00" maxParentChildStudyModDate="2020-09-01T10:56:53-05:00" handle="HMP_ForegutEsophagealAdenocarcinoma" num_participants=""><StudyInfo accession="phs000260.v1.p1" parentAccession="phs000260.v1.p1"><StudyNameEntrez>Foregut microbiome in development of esophageal adenocarcinoma</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="No"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="No"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>sra</StudyType><StudyType>metagenomics</StudyType></StudyTypes><SraStorages/><Description>
&lt;p&gt;The distal esophagus is an important anatomical area where gastric acid reflux can cause reflux esophagitis (RE),   Barrett&amp;#39;s esophagus (BE) (intestinal metaplasia), and esophageal adenocarcinoma (EA). The incidence of EA has   increased 6-fold in the U.S. since the 1970s, parallel to a significant increase in the prevalence of gastroesophageal   reflux diseases (GERD). Although specific host factors might predispose one to disease risk, such a rapid increase in   incidence must be predominantly environmental. The cause remains unknown. Our hypothesis is that changes in the   foregut microbiome are associated with EA and its precursors, RE and BE in the GERD sequence.&lt;/p&gt;   &lt;p&gt;We will conduct a case control study to demonstrate the microbiome-disease association in every stage of GERD   sequence as well as analyze the trend in changes in the microbiome along disease progression toward EA.&lt;/p&gt;   &lt;p&gt;Specific Aim 1. To conduct a comprehensive population survey of the foregut microbiome and demonstrate its   association with GERD sequence, by 16S rRNA gene survey. We will analyze samples of the foregut microbiome at   three anatomic loci: mouth, distal esophagus, and gastric corpus. Changes of the microbiota in the distal   esophagus will be correlated with the phenotypes. Spatial relationship between the esophageal microbiota and   upstream (mouth) and downstream (stomach) foregut microbiotas as well as temporal stability of the   microbiome-disease association will also be examined.&lt;/p&gt;   &lt;p&gt;Specific Aim 2. To define distal esophageal metagenome and demonstrate its association with GERD sequence,   by shotgun metagenomic analysis. We will first classify samples of the metagenome into metagenotypes by   between-sample k-mer distance and correlate the metagenotypes with the four phenotypes. Subsequent detailed analyses   will include pathway-disease and gene-disease associations. DNA viruses and fungi, if identified, also will be   correlated with the phenotypes.&lt;/p&gt;   &lt;p&gt;A significant association between the foregut microbiome and GERD sequence, if demonstrated, will be the   first step for eventually testing the causal hypothesis that an abnormal microbiome is required for the development   of the sequence of phenotypic changes toward EA.&lt;/p&gt;   &lt;p&gt;If EA and its precursors represent a microbial ecological disease, treating the cause of GERD might become   possible, for example, by normalizing the microbiome through use of antibiotics, probiotics, or prebiotics.   Causative therapy for GERD could prevent its progression and reverse the current trend of increasing incidence   of EA.&lt;/p&gt;
 </Description><StudyHistory>
&lt;p&gt;Gastroesophageal reflux disorders (GERD) refer to a sequence of diseases arising from gastric reflux, including   reflux esophagitis (RE), Barrett&amp;#39;s esophagus (intestinal metaplasia) (BE), and its downstream sequelum esophageal   adenocarcinoma (EA).  The incidence of EA has increased &amp;gt; 6-fold in the U.S. since the 1970s (1), parallel to   an increasing prevalence of RE (2).  Despite numerous studies, no explanation has been found for the increase.   Although prevalence of RE is increasing in both men and women, strong gender disparity with male predominance   is obvious at the stages of BE and EA for reasons unknown (3-5).  The current strategy for dealing with the   continuum of progression of GERD-related problems is limited to passive observation and symptomatic treatment,   such as using proton pump inhibitors, and has been ineffective in preventing the increase in the incidence of EA.   GERD, similar to other chronic diseases, likely has a multi-factorial etiology.  Although host factors likely   play a role, such a rapid increase in incidence must be predominantly environmental.  Conventional studies   have identified numerous risk factors, but their association with GERD is moderate (Table 1). The main   factor(s) remain to be identified. The role of the microbiome in the development of inflammation-related   cancers has been suggested by recent studies in some mouse models that mimic inflammatory bowel diseases (6).   The development of mucosal inflammation and adenocarcinoma requires both a trigger (chemical or genetic)   and the presence of commensal bacteria.  Although human exposure to several exogenous pathogens has been   monitored, there has been little attention paid to changes in the indigenous microbiome.  This is partly   due to the complexity and difficulties in culture and analysis of the human microbiome.&lt;/p&gt;   &lt;p&gt;Among the environmental agents that have been considered are microbes.  The human body can be viewed   as a superorganism composed of an amalgam of both microbial and Homo sapiens cells.  Our relationship   with bacteria can be considered to span a broad spectrum, from mutualism to pathogenicity (7).  There   are currently two theories to explain bacterial diseases.  The classic pathogen theory, largely   attributed to Koch, requires the presence of specific pathogens, such as Mycobacterium tuberculosis   or Bacillus anthracis (8).  Alternatively, the microecological disease or "pathogenic microbial community"   theory is a new concept in which the entire community contributes to pathogenicity although no individual   community members can be categorized as classic pathogens (9).&lt;/p&gt;   &lt;p&gt;Non-pathogenic bacteria do not have classically defined virulence factors but may harm the host by their   basic metabolic activities or structural components.  The gut microbiota in ob/ob mice, for example, has   an increased capacity to harvest energy from the diet and might play a role in the pathophysiology of   obesity (10).  Also, a structural component of the gram-negative outer membrane from non-pathogenic bacteria,   lipopolysaccharide (LPS), can induce abnormal relaxation of the lower esophageal sphincter via activation of   the iNOS pathway (11) and (12) delay gastric emptying through the COX-2 pathway. Both effects increase the   chance of reflux.&lt;/p&gt;   &lt;p&gt;We have endeavored to understand the bacterial-host relationship in GERD in a stepwise way.  First,   we performed a comprehensive study of the microbiota in the distal esophagus and demonstrated its complexity,   despite little prior knowledge (13-14).  Surprisingly, the esophageal microbiota is comparable in complexity   to those found in the mouth, stomach, colon, vagina, and skin.  Collectively, nine phyla were observed,   represented by 166 species. The distal esophagus could harbor &amp;gt; 200species, as predicted by the Chao-1   richness estimator.   Second, we have demonstrated that in a high-risk population (elderly males) the   esophageal microbiota can be classified into two types with the use of both unsupervised and phenotype-directed   analyses, and that the type II biota is the strongest (OR &amp;gt;15) amongst all known environmental factors that are   associated with the pathological changes related to RE and BE.&lt;/p&gt;
 </StudyHistory><Attributions><Header title="Co-Principal Investigators"><AttrName>Zhiheng Pei, MD, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Principal Investigators"><AttrName>Karen Nelson, PhD</AttrName><Institution>J Craig Venter Institute, Maryland, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Liying Yang, MD, MS</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Stuart Brown, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Gary Andersen, PhD</AttrName><Institution>Lawrence Berkeley National Lab, California, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Eion Brodie, PhD</AttrName><Institution>Lawrence Berkeley National Lab, California, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Page Caufield, DDS, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Yu Chen, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Todd Desantis, MS</AttrName><Institution>Lawrence Berkeley National Lab, California, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Fritz Francois, MD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Xiaoyu Li, MD</AttrName><Institution>University of Florida - Jacksonville, Florida, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Mengling Liu, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Michael Poles, MD, PhD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Morris Traube, MD</AttrName><Institution>NYU Langone Medical Center, New York, NY, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Patrick Yachimski, MD, MPH</AttrName><Institution>Vanderbilt University Medical Center, Tennessee, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Weimin Ye, MD, PhD</AttrName><Institution>Karolinska Instituet, Sweden</Institution></Header><Header title="Co-Investigators"><AttrName>Shibu Yooseph, PhD</AttrName><Institution>J Craig Venter Institute, Maryland, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Steven Moss, MD</AttrName><Institution>Brown University/Rhode Island Hospital, Rhode Island, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Sharmila Anandasabapathy, MD</AttrName><Institution>Mount Sinai Medical Center, New York, USA</Institution></Header></Attributions><StudyURLs><Url name="Foregut Microbiome in the Development of Esophageal Adenocarcinoma" url="http://gerd.med.nyu.edu/"/></StudyURLs><Publications><Publication><Pubmed pmid="15657344"/></Publication><Publication><Pubmed pmid="17142109"/></Publication><Publication><Pubmed pmid="15545159"/></Publication><Publication><Pubmed pmid="9827707"/></Publication><Publication><Pubmed pmid="16221805"/></Publication><Publication><Pubmed pmid="17106919"/></Publication><Publication><Pubmed pmid="11352068"/></Publication><Publication><Pubmed pmid="16112578"/></Publication><Publication><Pubmed pmid="16497592"/></Publication><Publication><Pubmed pmid="17183312"/></Publication><Publication><Pubmed pmid="11123195"/></Publication><Publication><Pubmed pmid="11959090"/></Publication><Publication><Pubmed pmid="16437628"/></Publication><Publication><Pubmed pmid="15016918"/></Publication><Publication><Pubmed pmid="2161310"/></Publication><Publication><Pubmed pmid="10364004"/></Publication><Publication><Pubmed pmid="1699893"/></Publication><Publication><Pubmed pmid="12916665"/></Publication><Publication><Journal authors="Glickman JN and Odze RD" title="Epithelial neoplasms of the esophagus" journal="Surgical Pathology of the GI tract, Liver, Biliary tract, and Pancreas Odze RD, Goldblum JR, and Crawford JM.  Philadelphia: Saunders, 2004."/></Publication><Publication><Pubmed pmid="1882791"/></Publication><Publication><Pubmed pmid="19394334"/></Publication><Publication><Pubmed pmid="19563840"/></Publication><Publication><Journal authors="Tack J and Carethers JM" title="Different Microbiome Patterns in Normal, Inflammed, and Barrett's Esophagus" journal="Gastroenterology. 2009;137:398-399"/></Publication><Publication><Pubmed pmid="19415112"/></Publication><Publication><Pubmed pmid="19914921"/></Publication><Publication><Pubmed pmid="20418441"/></Publication><Publication><Journal authors="Nossa CW, Oberdorf WE, Yang L, Aas JA, Paster BJ, DeSantis TZ, Brodie E, Lee P, Malamud D, Poles M, Pei Z" title="Design of 16S rRNA gene primers for 454-pyrosequencing of human foregut microbiome" journal="World Journal of Gasteroenterology 2010. In press"/></Publication></Publications><Funding>UH2 CA140233-01</Funding></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="PEIZ01" aid="2" auth="eRA" login="PEIZ01" fname="ZHIHENG" lname="PEI" email="zhiheng.pei@med.nyu.edu"><Role>PI</Role><Organization>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</Organization></Person><Person nedid="0010142285" aid="1" auth="cit" login="howcrofk" fname="Thomas" mname="K" lname="Howcroft" email="howcrofk@exchange.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="2000633685" aid="1" auth="cit" login="buccinild" fname="Laura" mname="Danielle" lname="Buccini" email="none"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="12 months"><DUC><File uri="dbgapssws.cgi?blob_id=6328&amp;file=get&amp;page=file" filename="Data Use Certification - Foregut Microbiome in Development of Esophageal Adenocarcinoma - Revised 7.19.10.doc" md5="a5779b06d559fe32e1f8f3f958297a95" size="81920" modDate="2010-07-19T17:16:02-05:00" content-type="application/msword"/></DUC><ConsentGroup uid="140" CGType="cg_class_other" title="Human Microbiome Research" name="HMP" dac_uid="62" dac_name="eNCI DAC" irb-approval-required="No"><Use-Restriction>These data may be used only for studies related to the human microbiome. Research aimed at understanding the relationships between humans and microbes or identifying the organisms living in or on humans.  This includes studies to enumerate the population of the human microbiome, metagenomic studies, functional studies related to the human microbiome, studies that evaluate the impact of the human microbiome on human phenotypes or disease states, studies to develop technologies and analytic tools that can be used in human microbiome research, and studies that will use the data in a way that will contribute to the further understanding of the human microbiome through comparison with non-human data sets.  </Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>